| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ERCC1 |
| Uniprot No | P07992 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-273aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMDPGKD KEGVPQPSGP PARKKFVIPL DEDEVPPGVA KPLFRSTQSL PTVDTSAQAA PQTYAEYAIS QPLEGAGATC PTGSEPLAGE TPNQALKPGA KSNSIIVSPR QRGNPVLKFV RNVPWEFGDV IPDYVLGQST CALFLSLRYH NLHPDYIHGR LQSLGKNFAL RVLLVQVDVK DPQQALKELA KMCILADCTL ILAWSPEEAG RYLETYKAYE QKPADLLMEK LEQDFVSRSL EQLIAASRED LALCPGLGPQ KARRLFDVLH EPFLKVP |
| 预测分子量 | 33 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ERCC1重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Expression and Purification of Recombinant ERCC1 for Structural and Functional Studies*
**作者**：Niedernhofer, L.J., et al.
**摘要**：该研究描述了ERCC1重组蛋白在大肠杆菌中的高效表达和纯化方法，验证了其与XPF蛋白形成功能复合物的能力，并用于体外DNA损伤修复分析，证实其在核苷酸切除修复中的关键作用。
---
2. **文献名称**：*Structural Basis of ERCC1-XPF Interaction and Its Role in DNA Repair*
**作者**：Tsodikov, O.V., Enzlin, J.H., Schärer, O.D.
**摘要**：通过X射线晶体学解析ERCC1-XPF重组蛋白复合物的结构，揭示了二者结合界面的关键氨基酸残基，阐明了该复合物在DNA损伤识别和切割中的分子机制。
---
3. **文献名称**：*ERCC1 Recombinant Protein as a Predictive Biomarker for Platinum-Based Chemotherapy Response*
**作者**：Olaussen, K.A., et al.
**摘要**：研究利用重组ERCC1蛋白开发体外检测方法，证明肿瘤细胞中ERCC1表达水平与铂类药物耐药性相关，提示其在个性化癌症治疗中的潜在应用价值。
---
4. **文献名称**：*Functional Analysis of ERCC1 Missense Variants Using Recombinant Protein Assays*
**作者**：McNeil, E.M., Melton, D.W.
**摘要**：通过构建ERCC1突变体重组蛋白，结合体外DNA修复实验，评估了不同突变对ERCC1-XPF复合物功能的影响，为遗传性DNA修复缺陷疾病的机制提供依据。
---
以上文献涵盖ERCC1重组蛋白的制备、结构解析、功能研究及临床应用方向。
**Background of ERCC1 Recombinant Protein**
ERCC1 (Excision Repair Cross-Complementation Group 1) is a critical protein involved in DNA repair mechanisms, particularly in nucleotide excision repair (NER) and the repair of DNA interstrand crosslinks (ICLs). It functions as a structure-specific endonuclease, forming a heterodimeric complex with XPF (xeroderma pigmentosum group F protein). This ERCC1-XPF complex recognizes and cleaves damaged DNA strands, enabling the removal of bulky DNA lesions caused by UV radiation, chemical agents, or oxidative stress.
Recombinant ERCC1 protein is engineered using biotechnological methods, often expressed in *E. coli* or mammalian cell systems, to produce a purified, functional form for research and therapeutic applications. Its recombinant version retains the ability to interact with XPF and participate in DNA repair processes *in vitro* or *in vivo*. Studies leveraging ERCC1 recombinant protein have elucidated its role in maintaining genomic stability, cancer biology, and cellular responses to chemotherapy.
Clinically, ERCC1 expression levels are linked to resistance to platinum-based chemotherapies (e.g., cisplatin), as efficient DNA repair in cancer cells reduces drug efficacy. Thus, recombinant ERCC1 is used to explore mechanisms of chemoresistance and develop biomarkers for personalized cancer treatment. Additionally, ERCC1 deficiencies are associated with accelerated aging disorders (e.g., Cockayne syndrome) and sensitivity to environmental carcinogens, highlighting its broader relevance in human health.
Overall, ERCC1 recombinant protein serves as a vital tool for dissecting DNA repair pathways, advancing cancer research, and informing therapeutic strategies.
×
